Researchers Identify New Enzyme Target That Reduces Alzheimer's Plaques in Lab Studies
Similar Articles
Researchers Identify Brain Cell Process That Removes Alzheimer's Plaques in Mice
Arginine Shows Promise in Reducing Alzheimer's Plaques in Animal Studies
Research Identifies Protein Target That Improves Memory in Alzheimer's Mouse Model
Anti-Amyloid Drugs Show Limited Benefit for Early Alzheimer's, Carry Side Effects
Engineered Nanoparticles Show Promise in Restoring Brain Waste Removal in Alzheimer's Mouse Model
Scientists have discovered that targeting a specific brain enzyme called IDOL in neurons significantly reduces amyloid plaques, a key hallmark of Alzheimer's disease. The research suggests a potential new pathway for drug development, distinct from existing FDA-approved treatments. The team is now exploring several approaches to develop drugs that target this enzyme.
Facts First
- Targeting the IDOL enzyme in neurons reduced amyloid plaques in laboratory models of Alzheimer's disease.
- The effect was most significant when IDOL was removed from neurons, not from the brain's immune cells (microglia).
- Deleting IDOL in neurons also lowered levels of apolipoprotein E (APOE), a protein linked to Alzheimer's risk.
- Researchers are exploring several drug development approaches to target the IDOL enzyme.
- Future studies will test safety and efficacy of potential compounds in preclinical models.
What Happened
Researchers at the Indiana University School of Medicine found that removing an enzyme called IDOL from neurons in laboratory models of Alzheimer's disease significantly reduced amyloid plaques. The most significant effects occurred when IDOL was deleted from neurons rather than from microglia, the brain's immune cells. Deleting IDOL in neurons also lowered levels of apolipoprotein E (APOE), a protein where the APOE4 variant is considered the greatest genetic risk factor for late-onset Alzheimer's. The findings were published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
Why this Matters to You
This discovery could lead to a new class of Alzheimer's treatments that work differently from current FDA-approved drugs. For individuals with a family history of Alzheimer's or those concerned about cognitive decline, this research represents a potential future avenue for slowing or preventing the disease. The focus on APOE, a major genetic risk factor, means future therapies might be particularly beneficial for people with that specific risk profile.
What's Next
The research team is exploring several approaches for developing drugs that target the IDOL enzyme. Future studies will focus on testing the safety of potential compounds and evaluating their efficacy in preclinical models. Scientists also plan to investigate whether blocking IDOL can preserve synaptic connections between neurons and reduce tau pathology, another damaging feature of Alzheimer's disease.